1. 290 Development and first-in-human characterization of an ICOSL and BAFF bispecific inhibitor AMG 570 for SLE treatment. (April 2019) Authors: Cheng, Laurence E; Hsu, Hailing; Kankam, Martin; Siebers, Nicholas; Stoltz, Randall; Abuqayyas, Lubna; Ertik, Bella; Sullivan, Barbara; Zhou, Lei; Parnes, Jane R Journal: Lupus science & medicine Issue: Volume 6(2019)supplement 1 Page Start: A210 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers. (November 2017) Authors: Mallory, Raburn M.; Ali, S.Omar; Takas, Therese; Kankam, Martin; Dubovsky, Filip; Tseng, Leo Journal: Biologicals Issue: Volume 50(2017) Page Start: 81 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects. (6th September 2020) Authors: Garey, Kevin W; Begum, Khurshida; Lancaster, Chris; Gonzales-Luna, Anne; Bui, Dinh; Mercier, Julie; Seng Yue, Corinne; Ducharme, Murray P; Hu, Ming; Vince, Bradley; Silverman, Michael H; Alam, M Jahangir; Kankam, Martin Journal: Journal of antimicrobial chemotherapy Issue: Volume 75:Number 12(2020) Page Start: 3635 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Anti‐KIT monoclonal antibody CDX‐0159 induces profound and durable mast cell suppression in a healthy volunteer study. Issue 8 (3rd March 2022) Authors: Alvarado, Diego; Maurer, Marcus; Gedrich, Richard; Seibel, Scott B.; Murphy, Michael B.; Crew, Linda; Goldstein, Joel; Crocker, Andrea; Vitale, Laura A.; Morani, Pamela A.; Thomas, Lawrence J.; Hawthorne, Thomas R.; Keler, Tibor; Young, Diane; Crowley, Elizabeth; Kankam, Martin; Heath‐Chiozzi, Margo Journal: Allergy Issue: Volume 77:Issue 8(2022) Page Start: 2393 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study. Issue 2 (13th March 2023) Authors: Gillies, Hunter; Niven, Ralph; Dake, Benjamin T.; Chakinala, Murali M.; Feldman, Jeremy P.; Hill, Nicholas S.; Hoeper, Marius M.; Humbert, Marc; McLaughlin, Vallerie V.; Kankam, Martin Journal: ERJ open research Issue: Volume 9:Issue 2(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Effect of Food on the Pharmacokinetics of Quizartinib. Issue 2 (8th January 2020) Authors: Li, Jianke; Holmes, Melissa; Kankam, Martin; Trone, Denise; Mendell, Jeanne; Gammon, Guy Journal: Clinical pharmacology in drug development Issue: Volume 9:Issue 2(2020) Page Start: 277 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite. Issue 9 (23rd July 2019) Authors: Li, Jianke; Kankam, Martin; Trone, Denise; Gammon, Guy Journal: British journal of clinical pharmacology Issue: Volume 85:Issue 9(2019) Page Start: 2108 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Pharmacokinetics and Safety of Vibegron 75 mg Administered as an Intact or Crushed Tablet in Healthy Adults. Issue 11 (14th September 2022) Authors: King, Jennifer; Walker, Ann; Aikin, Dorothy; Haag‐Molkenteller, Cornelia; Kankam, Martin Journal: Clinical pharmacology in drug development Issue: Volume 11:Issue 11(2022) Page Start: 1349 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout. (7th May 2018) Authors: Kankam, Martin; Hall, Jesse; Gillen, Michael; Yang, Xiaojuan; Shen, Zancong; Lee, Caroline; Liu, Sha; Miner, Jeffrey N.; Walker, Susan; Clauson, Vicki; Wilson, David; Nguyen, Mai Journal: Journal of clinical pharmacology Issue: Volume 58:Number 9(2018) Page Start: 1214 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Issue 10286 (8th May 2021) Authors: Enebo, Lone B; Berthelsen, Kasper K; Kankam, Martin; Lund, Michael T; Rubino, Domenica M; Satylganova, Altynai; Lau, David C W Journal: Lancet Issue: Volume 397:Issue 10286(2021) Page Start: 1736 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗